COVID-19 vaccine response in pregnant and lactating women: a cohort study
ABSTRACT Background Pregnant and lactating women were excluded from initial COVID-19 vaccine trials; thus, data to guide vaccine decision-making are lacking. We sought to evaluate the immunogenicity and reactogenicity of COVID-19 mRNA vaccination in pregnant and lactating women.Methods 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers. Titers of SARS-CoV-2 Spike and RBD IgG, IgA and IgM were quantified in participant sera (N=131), umbilical cord sera (N=10), and breastmilk (N=31) at baseline, 2nd vaccine dose, 2-6 weeks post 2nd vaccine, and delivery by Luminex, and confirmed by ELISA. Titers were compared to pregnant women 4-12 weeks from native infection (N=37). Post-vaccination symptoms were assessed. Kruskal-Wallis tests and a mixed effects model, with correction for multiple comparisons, were used to assess differences between groups.Results Vaccine-induced immune responses were equivalent in pregnant and lactating vs non-pregnant women. All titers were higher than those induced by SARS-CoV-2 infection during pregnancy. Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. SARS-CoV-2 specific IgG, but not IgA, increased in maternal blood and breastmilk with vaccine boost. No differences were noted in reactogenicity across the groups.Conclusions COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placental and breastmilk..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gray, Kathryn J. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.03.07.21253094 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020104278 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020104278 | ||
| 003 | DE-627 | ||
| 005 | 20240425104757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.03.07.21253094 |2 doi | |
| 035 | |a (DE-627)XBI020104278 | ||
| 035 | |a (biorXiv)10.1101/2021.03.07.21253094 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gray, Kathryn J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine response in pregnant and lactating women: a cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background Pregnant and lactating women were excluded from initial COVID-19 vaccine trials; thus, data to guide vaccine decision-making are lacking. We sought to evaluate the immunogenicity and reactogenicity of COVID-19 mRNA vaccination in pregnant and lactating women.Methods 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers. Titers of SARS-CoV-2 Spike and RBD IgG, IgA and IgM were quantified in participant sera (N=131), umbilical cord sera (N=10), and breastmilk (N=31) at baseline, 2nd vaccine dose, 2-6 weeks post 2nd vaccine, and delivery by Luminex, and confirmed by ELISA. Titers were compared to pregnant women 4-12 weeks from native infection (N=37). Post-vaccination symptoms were assessed. Kruskal-Wallis tests and a mixed effects model, with correction for multiple comparisons, were used to assess differences between groups.Results Vaccine-induced immune responses were equivalent in pregnant and lactating vs non-pregnant women. All titers were higher than those induced by SARS-CoV-2 infection during pregnancy. Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. SARS-CoV-2 specific IgG, but not IgA, increased in maternal blood and breastmilk with vaccine boost. No differences were noted in reactogenicity across the groups.Conclusions COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placental and breastmilk. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bordt, Evan A. |e verfasserin |4 aut | |
| 700 | 1 | |a Atyeo, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Deriso, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Akinwunmi, Babatunde |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Baez, Aranxta Medina |e verfasserin |4 aut | |
| 700 | 1 | |a Shook, Lydia L. |e verfasserin |4 aut | |
| 700 | 1 | |a Cvrk, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a James, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a De Guzman, Rose M. |e verfasserin |4 aut | |
| 700 | 1 | |a Brigida, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Diouf, Khady |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfarb, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Bebell, Lisa M. |e verfasserin |4 aut | |
| 700 | 1 | |a Yonker, Lael M. |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Rabi, Sayed A. |e verfasserin |4 aut | |
| 700 | 1 | |a Elovitz, Michal A. |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Edlow, Andrea G. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ajog.2021.03.023 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.03.07.21253094 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||